

oxybate Products (Xyrem[®], Xywav[®], Lumryz[™])

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider sodium oxybate (Xyrem[®] and its authorized generic)[‡]; calcium, magnesium, potassium, and sodium oxybates solution (Xywav[®])[‡]; and sodium oxybate extended release (Lumryz[™])[‡] to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for sodium oxybate (Xyrem and its authorized generic); calcium, magnesium, potassium, and sodium oxybates solution (Xywav); and sodium oxybate extended release (Lumryz) will be considered when the following are met for the requested drug:

- For **Xyrem** requests:
 - Patient has a diagnosis of Narcolepsy type 1 (narcolepsy with cataplexy) with presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; OR
*(Note: The 3 month timeframe is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*
 - Patient has a diagnosis of Narcolepsy type 2 (narcolepsy without cataplexy) with the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; AND
 - Patient has tried and failed (inadequate response or intolerance) at least ONE of the following generic medications unless there is clinical evidence or patient history that suggests the use of the generic alternatives will be ineffective or cause an adverse reaction to the patient: modafinil, armodafinil, methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine salt; OR

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

*(Note: The 3 month timeframe and the requirement for prior use of at least one generic-alternative therapy are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met)*

- For **Xywav** requests:

- Patient has a diagnosis of Narcolepsy type 1 (narcolepsy with cataplexy) with presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; OR

*(Note: The 3 month timeframe is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

- Patient has a diagnosis of Narcolepsy type 2 (narcolepsy without cataplexy) with the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; AND

- Patient has tried and failed (inadequate response or intolerance) at least ONE of the following generic medications unless there is clinical evidence or patient history that suggests the use of the generic alternatives will be ineffective or cause an adverse reaction to the patient: modafinil, armodafinil, methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine salt; OR

*(Note: The 3 month timeframe and the requirement for prior use of at least one generic-alternative therapy are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met)*

- Patient has a diagnosis of idiopathic hypersomnia and BOTH of the following:

- Patient is 18 years of age or older; AND
- Patient has tried and failed (e.g., intolerance or inadequate response) at least ONE of the following generic medications unless there is clinical evidence or patient history that suggests the use of the generic alternatives will be ineffective or cause an adverse reaction to the patient: modafinil, armodafinil, methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine salt.

*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*

- For **Lumryz** requests:

- Patient is 7 years of age or older; AND
- Patient has a diagnosis of Narcolepsy type 1 (narcolepsy with cataplexy) with presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing that is consistent with national guidelines; OR

*(Note: The 3 month timeframe is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

- Patient has a diagnosis of Narcolepsy type 2 (narcolepsy without cataplexy) with the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; AND
 - Patient has tried and failed (inadequate response or intolerance) at least ONE of the following generic medications unless there is clinical evidence or patient history that suggests the use of the generic alternatives will be ineffective or cause an adverse reaction to the patient: modafinil, armodafinil, methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine salt.
*(Note: The 3 month timeframe and the requirement for prior use of at least one generic-alternative therapy are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met)*
- For **Xyrem authorized generic** requests:
 - Patient has a diagnosis of Narcolepsy type 1 (narcolepsy with cataplexy) with presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; OR
*(Note: The 3 month timeframe is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*
 - Patient has a diagnosis of Narcolepsy type 2 (narcolepsy without cataplexy) with the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months that is confirmed by diagnostic testing consistent with national guidelines; AND
*(Note: The 3 month timeframe is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*
 - Patient has tried and failed (inadequate response or intolerance) at least ONE of the following generic medications unless there is clinical evidence or patient history that suggests the use of the generic alternatives will be ineffective or cause an adverse reaction to the patient: modafinil, armodafinil, methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine salt; AND
 - Patient has tried and failed (inadequate response or intolerance) solriamfetol (Sunosi[®])[‡] unless there is clinical evidence or patient history that suggests the use of solriamfetol (Sunosi) will be ineffective or cause an adverse reaction to the patient; AND
 - Patient has tried and failed (inadequate response or intolerance) brand Xyrem or Xywav unless there is clinical evidence or patient history that suggests the use of Xyrem or Xywav will be ineffective or cause an adverse reaction to the patient; AND
*(Note: These specific patient selection criteria are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met.)*
 - Sodium oxybate will not be used in combination with another oxybate product (Xyrem, Xywav, Lumryz).

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of sodium oxybate (Xyrem and its authorized generic); calcium, magnesium, potassium, and sodium oxybates solution (Xywav); and sodium oxybate extended release (Lumryz) WITHOUT a trial and failure of at least one generic drug for Narcolepsy Type 2 to be **not medically necessary**.**

Based on review of available data, the Company considers the use of sodium oxybate (Xyrem and its authorized generic); calcium, magnesium, potassium, and sodium oxybates solution (Xywav); and sodium oxybate extended release (Lumryz) WITHOUT the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months for Narcolepsy Type 1 or Narcolepsy Type 2 to be **not medically necessary**.**

Based on review of available data, the Company considers the use of calcium, magnesium, potassium, and sodium oxybates solution (Xywav) for the treatment of idiopathic hypersomnia WITHOUT a trial and failure of at least one generic drug for idiopathic hypersomnia to be **not medically necessary**.**

Based on review of available data, the Company considers the use of Sodium Oxybate (Xyrem's authorized generic) when the patient has not tried and failed Sunosi AND brand Xyrem or Xywav to be **not medically necessary**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of sodium oxybate (Xyrem and its authorized generic); calcium, magnesium, potassium, and sodium oxybates solution (Xywav); and sodium oxybate extended release (Lumryz) for any indication other than the FDA approved indications to be **investigational**.*

Background/Overview

The products targeted by this policy (Xyrem, its authorized generic, Xywav, and Lumryz) are gamma hydroxybutyrate (GHB) salts approved for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy. Xywav has the additional indication of idiopathic hypersomnia. Both Xyrem and Xywav have the same concentration of oxybate with Xyrem including only sodium cations and Xywav including a mix of calcium, magnesium, potassium, and sodium cations. According to the manufacturer, Xywav has 92% less sodium, which may be important for patients sensitive to salt intake (e.g., those with heart failure, hypertension, or renal impairment). Lumryz is an extended release suspension of sodium oxybate that can be administered once per night instead of the twice nightly dosing required by the other products.

The mechanism of action of these products in narcolepsy is unknown. It is hypothesized that the therapeutic effects are mediated through GABA_B actions at noradrenergic and dopaminergic neurons and also at thalamocortical neurons. Guidelines from the American Academy of Sleep Medicine

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

have not yet been updated to include Xywav, but list Xyrem as an effective treatment of cataplexy, daytime sleepiness, and disrupted sleep due to narcolepsy. The guidelines also list modafinil type products as effective for the treatment of daytime sleepiness due to narcolepsy. Amphetamine, dextroamphetamine, their combo, and methylphenidate are considered effective for the treatment of daytime sleepiness as well. For narcolepsy type 2, the generically available alternatives are a more economical option.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Xyrem was approved in 2002 for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy. Xywav was approved in 2020 for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. In 2021, Xywav was approved for the treatment of idiopathic hypersomnia in adults. Lumryz was approved in May 2023 for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. In October 2024, Lumryz's FDA approved indication was further expanded to include pediatric patients 7 years of age and older.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

The intent of this policy is to ensure that sodium oxybate (Xyrem and its authorized generic); calcium, magnesium, potassium, and sodium oxybates solution (Xywav); and sodium oxybate extended release (Lumryz) are being used according to the FDA approved package insert indication as well as to ensure that more economical, yet equally efficacious alternatives are being used where applicable.

References

1. Xyrem [package insert]. Jazz Pharmaceuticals, Inc. Palo Alto, CA. Updated September 2020.
2. Morgenthaler TI, Kapur VK, Brown TM, et al. Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin: An American Academy of Sleep Medicine Report. Available at: http://www.aasmnet.org/Resources/PracticeParameters/PP_Narcolepsy.pdf. Accessed on November 13, 2015.
3. Wise MS, Arand DL, Auger R, et al. Treatment of narcolepsy and other hypersomnias of central origin: An American Academy of Sleep Medicine Review. Available at: http://www.aasmnet.org/Resources/PracticeParameters/Review_Narcolepsy.pdf. Accessed on November 13, 2015.

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

4. Xywav [package insert]. Jazz Pharmaceuticals, Inc. Palo Alto, CA. Updated October 2022.
5. Xyrem/Xywav Prior Authorization Policy. Express Scripts. Updated February 2022.
6. Lumryz [package insert]. Avadel CNS Pharmaceuticals, LLC. Chesterfield MO. Updated October 2024.

Policy History

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

09/08/2016	Medical Policy Committee review
09/21/2016	Medical Policy Implementation Committee approval. New policy.
09/07/2017	Medical Policy Committee review
09/20/2017	Medical Policy Implementation Committee approval. No change to coverage.
09/06/2018	Medical Policy Committee review
09/19/2018	Medical Policy Implementation Committee approval. No change to coverage.
09/05/2019	Medical Policy Committee review
09/11/2019	Medical Policy Implementation Committee approval. No change to coverage.
09/03/2020	Medical Policy Committee review
09/09/2020	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/04/2021	Medical Policy Committee review
02/10/2021	Medical Policy Implementation Committee approval. Added new product, Xywav, to policy with relevant background information.
08/05/2021	Medical Policy Committee review
08/11/2021	Medical Policy Implementation Committee approval. Changed criterion requiring trial and failure of two generics to only require trial and failure of one generic. Also updated Xywav criteria to remove step through Xyrem.
08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/05/2023	Medical Policy Committee review
01/11/2023	Medical Policy Implementation Committee approval. Added criteria and background information for new indication for Xywav for idiopathic hypersomnia.
09/07/2023	Medical Policy Committee review
09/13/2023	Medical Policy Implementation Committee approval. Added new products, Lumryz and Sodium Oxybate authorized generic to policy with relevant criteria and background information. Updated criteria to clarify that diagnosis of narcolepsy should be consistent with national guidelines.
09/05/2024	Medical Policy Committee review
09/11/2024	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/03/2025	Medical Policy Committee review
04/09/2025	Medical Policy Implementation Committee approval. Updated Lumryz's age requirement criterion to reflect expanded approval in pediatric patients 7 years of age and older.

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

04/02/2026 Medical Policy Committee review

04/10/2026 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 04/2027

***Investigational** – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

****Medically Necessary** (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

oxybate Products (Xyrem[®], Xywav[®], Lumryz[™])

Policy # 00532

Original Effective Date: 01/01/2017

Current Effective Date: 05/01/2026

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.